Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue $ 64 $ 56
Operating expenses:    
Cost of revenue - sales 12 9
Cost of revenue - impairment of inventory 165
Research and development 455 1,454
Sales and marketing 151 842
General and administrative 1,472 1,945
Total costs and expenses 2,090 4,415
Loss from operations (2,026) (4,359)
Gain on change in estimated fair value of contingent royalty obligation 220
Finance expense, net (80) (239)
Foreign currency loss (7) (8)
Net loss (2,113) (4,386)
Deemed dividends from warrant issuance (5,508)
Net loss attributable to common shareholders $ (7,621) $ (4,386)
Basic and diluted loss per common share:    
Net loss - Basic $ (0.25) $ (13.81)
Net loss - Diluted (0.25) (13.81)
Basic loss per common share (0.88) (13.81)
Diluted loss per common share $ (0.88) $ (13.81)
Weighted average number of common shares outstanding, basic 8,613,204 317,547
Weighted average number of common shares outstanding, diluted 8,613,204 317,547